Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 13/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 12/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 3/20 | 0.80 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.80 |
| ▸ | BRAF known ✓ | P15056 | 1/20 | 0.80 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.80 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.80 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.80 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.85 |
| ▸ | RAD52 | P43351 | 1/20 | 0.85 |
| ▸ | ABL2 | P42684 | 4/20 | 0.80 |
| ▸ | PLK4 | O00444 | 1/20 | 0.80 |
| ▸ | DDX3X | O00571 | 1/20 | 0.80 |
| ▸ | GAK | O14976 | 1/20 | 0.80 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.80 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.80 |
| ▸ | CA12 | O43570 | 1/20 | 0.80 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846536 | 0.97 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL29410182 | 0.97 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| Imatinib SCHEMBL726190 | 0.92 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| Imatinib SCHEMBL29370699 | 0.92 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| Imatinib SCHEMBL29377238 | 0.92 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| Imatinib SCHEMBL1673189 | 0.92 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| Imatinib SCHEMBL15632914 | 0.92 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| Imatinib SCHEMBL1060852 | 0.92 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| Imatinib SCHEMBL8217 | 0.92 | ABL1 (1.00) | ABL1KITBCRLRRK2PDGFRA | |
| SCHEMBL3064834 | 0.92 | ABL1 (0.90) | ABL1KITBCRLRRK2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329661-B2 | N-phenyl-3-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | claimed |
| US-7312216-B2 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2007-12-25 | — | — | US | claimed |
| US-20070265292-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | BUERGER HANS M | 2007-11-15 | — | — | US | claimed |
| US-20060223818-A1 | N-phenyl-2-pyrimidine-amine derivatives | BUERGER HANS M | 2006-10-05 | — | — | US | claimed |
| US-20040102453-A1 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2004-05-27 | — | — | US | claimed |
| EP-1322634-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2003-07-02 | — | — | EP | claimed |
| WO-2002022597-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | claimed |
| EP-1322634-B1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2009-12-16 | — | — | EP | disclosed |
| US-7329661-B2 | N-phenyl-3-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-7312216-B2 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20070265292-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | BUERGER HANS M | 2007-11-15 | — | — | US | disclosed |
| US-20060223818-A1 | N-phenyl-2-pyrimidine-amine derivatives | BUERGER HANS M | 2006-10-05 | — | — | US | disclosed |
| US-7081532-B2 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2006-07-25 | — | — | US | disclosed |
| US-20040102453-A1 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2004-05-27 | — | — | US | disclosed |
| EP-1322634-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002022597-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102453-A1 | N-phenyl-2-pyrimidine-amine derivatives | NUDT1, PNP, TYMP | ABL1 68/4885KIT 352/4885BCR 4165/4885 |
| US-20060223818-A1 | N-phenyl-2-pyrimidine-amine derivatives | NUDT1, PNP, TYMP | ABL1 66/4885KIT 468/4885BCR 4195/4885 |
| US-20070265292-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, TYMP | ABL1 66/4885KIT 468/4885BCR 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.